

(19) **DANMARK**



Patent- og  
Varemærkestyrelsen

(10) **DK/EP 2247571 T3**

(12) Oversættelse af  
europæisk patentskrift

- 
- (51) Int.Cl.: *C 07 C 217/16 (2006.01)* *A 61 K 31/133 (2006.01)* *A 61 K 31/135 (2006.01)*  
*A 61 K 31/165 (2006.01)* *A 61 P 9/06 (2006.01)* *A 61 P 25/08 (2006.01)*  
*C 07 C 217/18 (2006.01)* *C 07 C 217/20 (2006.01)* *C 07 C 235/20 (2006.01)*  
*C 07 C 235/22 (2006.01)* *C 07 C 237/22 (2006.01)*
- (45) Oversættelsen bekendtgjort den: **2014-12-08**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2014-09-10**
- (86) Europæisk ansøgning nr.: **09704454.9**
- (86) Europæisk indleveringsdag: **2009-01-19**
- (87) Den europæiske ansøgnings publiceringsdag: **2010-11-10**
- (86) International ansøgning nr.: **PL2009000004**
- (87) Internationalt publikationsnr.: **WO2009093916**
- (30) Prioritet: **2008-01-22 PL 38430408**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR**
- (73) Patenthaver: **Uniwersytet Jagiellonski, Ul. Golebia 24, 31007 Krakow, Polen**  
**Waszkielewicz, Anna Maria, ul. Jana Pawla II 64, 32-091 Michalowice, Polen**
- (72) Opfinder: **MARONA, Henryk, os. 2-go Pulku Lotniczego 26/14, 31 - 867 Krakow, Polen**  
**KIEC-KONONOWICZ, Katarzyna, al. Zygmunta Krasinskiego 26/8, , 31 - 867 Krakow, Polen**  
**WASZKIELEWICK, Anna Maria, ul. Jana Pawla II 64, 32-091 Michalowice, Polen**
- (74) Fuldmægtig i Danmark: **PLOUGMANN & VINGTOFT A/S, Rued Langgaards Vej 8, 2300 København S, Danmark**
- (54) Benævnelse: **DERIVATER AF AMINOALKANOLER, FREMGANGSMÅDE TIL OPNÅELSE AF AMINOALKANOLER OG DERES ANVENDELSE**
- (56) Fremdragne publikationer:  
**EP-A- 1 072 591**  
**WO-A-2007/062399**  
**US-A- 3 453 308**  
**US-A- 4 118 511**  
**H.MARONA ET AL: "Preliminary evaluation of anticonvulsant activity of some aroxyacetamides and aroxyethylamines" ACTA POL PHARM, vol. 62, no. 5, 2005, pages 345-353, XP009119708**  
**H.MARON ET AL: "Synthesis and anticonvulsant activity of some aroxyacetamides and aroxyethylamines" ACTA POL PHARM, vol. 55, no. 6, 1998, pages 487-498, XP009119605 cited in the application**  
**E. PEKALA ET AL: "SYNTHESIS OF NEW N-ACYL DERIVATIVES OF DL-TRANS-1,2-AMINO-CYCLOHEXANOL" ACTA POL PHARM - DRUG RES, vol. 51, 1994, pages 339-342, XP009119607 cited in the application**  
**MARONA HENRYK ET AL: "SYNTHEIS OF SOME N-ACYL DERIVATIVES OF OPTICALLY ACTIVE TRANS-2-AMINO-1-CYCLOHEXANOLS" ACTA POL PHARM, vol. 53, 1996, pages 111-115, XP009119608 cited in the**

Fortsættes ...

application

ANNA M. WASZKIELEWICZ ET AL: "SYNTHESIS AND PRELIMINARY EVALUATION OF ANTICONVULSANT ACTIVITY OF SOME [4-(BENZYLOXY)BENZOYL]- AND [4-(BENZYLOXY)BENZYL]AMINOALKANOL DERIVATIVES" ACTA POL PHARM, vol. 64, no. 2, 2007, pages 147-157, XP009119647 cited in the application  
H.MARONA ET AL: "Anticonvulsant activity of some xanthone derivatives" BIOORG. MED. CHEM., vol. 16, no. 15, 2008, pages 7234-7244, XP002536021

**Description**

**[0001]** The subject of the invention is a group of new derivatives of aminoalkanols, more specifically [(phenoxy)alkyl]aminoalkanols and [(phenoxy)acyl]aminoalkanols, their method of obtaining and their use for production of a medicine which is used in the prophylaxis, prevention and/or treatment of diseases or symptoms having neurological background and for production a medicine with anticonvulsant activity, which is used in seizures of various origin, also in the limbic system, in myoclonic or sound-induced seizures, in psychomotor epilepsy, as well as relieving neuropathic or inflammatory pain.

**[0002]** Overview of literature concerning biological activity in a group of aminoalkanols indicates possibility to select compounds revealing anticonvulsant properties, e.g. among drugs stabilizing electric potential of cells exhibiting their own electric activity. Propranolol serves as an example, as it exhibits beneficial properties in treatment of hypertension and arrhythmia, as well as it reveals properties of preventing some kinds of seizures [1]. Similar profile can be seen with mexiletine exhibiting protection in MES, ScMet and sound-induced seizures [2]. It is important, that the mechanism responsible for inhibiting seizures in both propranolol and mexiletine is mainly inhibition of voltage-gated sodium channels, while in arrhythmia treatment both drugs act differently: via antagonism of  $\beta$ -adrenergic receptors or via opening potassium channels, respectively [3]. However, capability of mexiletine usage in epilepsy treatment is very low due to the fact that it lowers seizure threshold in a dose not much above ED<sub>50</sub> (maximum electroshock MES, mice, intraperitoneal) in spite of inhibiting focal seizures. This activity causes necessity to perform threshold tonic extension (TTE) test in preliminary pharmacological assays for all substances of similar structure, revealing anticonvulsant activity, in order to exclude this harmful pro-convulsant activity [4]. Moreover, in epilepsy treatment, using drugs like propranolol or mexiletine also exhibiting activity on the heart is not proper. Therefore, new structures should be modeled in such way, that they are active in Central Nervous System (CNS) only without interfering the Cardiovascular System (CVS).

**[0003]** Excluded from the subject solution compounds are known from the following documents: "Preliminary evaluation of anticonvulsant activity of some aminoalkanol derivatives" 15th International Symposium "Molecular and Physiological Aspects of Regulatory Processes of the Organism", Cracow, June 1-2, 2006, Anna M. Waszkielewicz, Marek Cegla, Henryk Marona; "Synthesis and Anticonvulsant Activity of 1,2-Aminoalkanol Derivatives" Acta Poloniae Pharmaceutica - Drug Res, 55, 487-498, 1998 Marona H, Antkiewicz-Michaluk L.; "Preliminary Evaluation of Anticonvulsant Activity of Some Aroxyacetamides and Aroxyethylamines" Acta Pol. Pharm. - Drug Res. 62: 345-352, 2005; D5: Marona H., Waszkielewicz AM, Szneler E and Polish Patent Application No. P 319 557 Marona Henryk, Filipek Barbara, Uniwersytet Jagielloński Collegium Medicum, Polsih Patent Office 1997.

**[0004]** Therefore, the basic purpose of the invention was to create new chemical compounds which are useful in therapy, especially in treatment or prevention of diseases or symptoms of neurological background. The invention concerns a group of substituted aminoalkanol derivatives, preferably (phenoxy)alkyl- and [(phenoxy)acyl]aminoalkanols, their pharmaceutically acceptable salts, capable for use in treatment or prevention of diseases of neurological background. New compounds described in the patent application, exhibit anticonvulsant activity in various models of seizures, including Maximum Electroshock Seizures (MES, mice, rats), hippocampal kindling seizures (rats), and contain some elements of the structures (aminoalkanol moieties, aroxyalkyl group) of some known drugs used in treatment of arrhythmia (propranolol, mexiletine), which exhibit proved anticonvulsant activity [1, 2]. The common typical feature of activity of the new substances as well as mentioned antiarrhythmic drugs is influence on cells exhibiting their own electrical activity (nerve cells). However, the antiarrhythmic drugs act centrally and peripherally, and the compounds presented in the invention - due to their lipophilicity - mainly within CNS.

**[0005]** The embodiment of such a stated goal and the solution of problems related to the prophylaxis, prevention or/and treatment of diseases or symptoms of neurological background have been achieved in the present invention. It was unexpected that such defined purpose has been achieved with the presented invention.

**[0006]** The subject matter of the invention is aminoalkanol derivative, selected from the group comprising:

- R,S-2N-[(2-chlor-6-methylphenoxy)ethyl]amino-1-butanol (26)*
- R,S-2N-[(2-chlor-6-methylphenoxy)ethyl]amino-1-butanol hydrochloride (26a)*
- R-(-)-2N-[(2-chlor-6-methylphenoxy)ethyl]amino-1-butanol (27)*
- R-(-)-2N-[(2-chlor-6-methylphenoxy)ethyl]amino-1-butanol hydrochloride (27a)*
- S-(+)-2N-[(2-chlor-6-methylphenoxy)ethyl]amino-1-butanol (28)*
- R,S-2N-[(2,6-dimethylphenoxy)acetyl]amino-1-propanol (60)*
- R-(+)-2N-[(2,6-dimethylphenoxy)acetyl]amino-1-propanol (61)*
- S-(-)-2N-[(2,6-dimethylphenoxy)acetyl]amino-1-propanol (62)*
- R,S-1N-[(2-chlor-6-methylphenoxy)acetyl]amino-2-butanol (72)*

**[0007]** Another subject matter of the invention is use of the compound as described above for production of a medicine which is used in the prophylaxis, prevention and/or treatment of diseases or symptoms of neurological background.

**[0008]** Preferably disease or symptom of neurological background is an epilepsy, especially grand-mal epilepsy, psychomotor epilepsy, focal seizures, status epilepticus, myoclonic seizures or seizures of various origin (sound, light, chemical stimulus, genetic origin, neuronal damage), as well as neuropathic or inflammatory pain.

**[0009]** Preferably produced medicine is an analgesic, antiinflammatory, anticonvulsant or antiepileptic.

5 **[0010]** Preferably disease or symptom is neuropathic pain, including pain of various ethiology: diabetic neuropathy, cancer pain, AIDS neuropathy, spinal cord injury, phantom limb pain, or fibromyalgia.

**[0011]** Another subject of the invention is method of obtaining derivatives of aminoalkanols, characterized in that N-alkylation of said aminoalkanols with appropriate (phenoxy)alkyl bromides is made, by adding 0.010 - 0.015 mole of appropriate (phenoxy)ethyl or 3-(phenoxy)propyl bromide into a 100 ml flask, then 0.010 - 0.015 mole of appropriate aminoalkanol and an excess of anh.  $K_2CO_3$ , then the mixture is heated in toluene under reflux for ca. 3-15 h, and left to cool down, afterwards silica gel is added and the mixture is heated again, the gel and precipitated KBr is filtered off and the remaining mixture is distilled into oily residue, then 10-20% HCl and active carbon is added and the mixture is heated, afterwards, the suspension is filtered off and the filtrate is alkalized with 5-20% NaOH in order to precipitate the free basis, which is extracted with benzene or toluene, the organic phase is dried (anh.  $MgSO_4$ ), and the organic solvent is distilled off until oily residue, which is crystallized.

**[0012]** Another subject of the invention is method of obtaining aminoalkanols, characterized in that N-Acetylation of said aminoalkanols or hydrochloride of amino acids esters with use of chloride of appropriate (phenoxy)alkanoic acid in biphasic environment (toluene/water) with presence of  $K_2CO_3$  is made, wherein 0.015 - 0.025 mole of appropriate aminoalkanol in 30 ml toluene is put in a flask, an excess of  $K_2CO_3$  is added dissolved in 50 ml of water, the mixture is cooled down and put on an stirrer, then the mixture is added by small amounts a solution of appropriate (phenoxy)acetic chloride in toluene, and the emulsion is left on the stirrer for ca. 0.5 h and afterwards it is heated, after cooling the organic phase is separated and dried with anh.  $MgSO_4$ , then the solvent is distilled off, and the residue is crystallized into a white precipitate of appropriate derivative.

**[0013]** The attached Figures facilitate a better understanding and present the nature of the presented invention.

Figure 1 presents results of formalin test for *R*-(-)-2-[(2,6-dimethylphenoxy)ethyl]amino-1-propanol.

Figure 2 presents results of formalin test for *R*,*S*-2-[(2-chlor-6-methylphenoxy)ethyl]amino-1-butanol.

Figure 3 presents results of comparison of feeling pain by mice after administration of compound 26 and known drugs.

30 **[0014]** Below there are example embodiments of the present invention described above.

**[0015]** Example 1. Synthesis of compounds according to the invention.

Synthesis of [(phenoxy)alkyl]aminoalkanols

35 **[0016]** Synthesis reactions in order to achieve appropriate [(phenoxy)alkyl]aminoalkanols were performed by a few methods, i.e.:

1) aminolysis of toluenesulphonate of appropriate (phenoxy)alkanols [5];

2) N-alkylation of appropriate aminoalkanols using appropriate (phenoxy)alkyl bromides published to pre-final stage which was modified [5];

3) reduction of appropriate [(phenoxy)acetamido]alkanols into appropriate amines using  $LiAlH_4$  in diethyl ether/ $N_2$  [6].

**[0017]** Some compounds were achieved in the form of hydrochlorides, using a saturated solution of HCl in ethanol or using gas HCl, and afterwards performing crystallization from mixture of ethyl acetate/EtOH (3:1).

45 **[0018]** In order to achieve compounds being racemates or enantiomers, commercially available aminoalkanols were used, except for *R*,*S*-1-amino-2-butanol, *R*-(-) and *S*-(+)-2-amino-1-butanol, as well as *D*,*L*-*trans*-cyclohexanolamine [7]. Some of the necessary reagents can be achieved according to formerly published procedures [5, 7, 8].

Synthesis of [(phenoxy)acetyl]aminoalkanols and some of their derivatives

50 **[0019]**

1) N-Acetylation of appropriate aminoalkanols is performed with use of chloride of appropriate (phenoxy)alkanoic acid in biphasic environment (toluene/water) with presence of  $K_2CO_3$  [6]. Product of the reaction is achieved by separation of the organic phase, washing with 10% of  $NaHCO_3$ , drying and evaporation into remaining which is furtherly crystallized from a mixture of n-heptane/toluene (1:2).

55 Necessary phenoxyalkanoic acids are achieved by O-alkylation of appropriate phenol (as sodium phenolate) with use of appropriate halogenoalkanoic acid in the form of sodium salt. Commercially available acids (in the form of

esters) were used.

2) Alternative and convenient method is reaction of mixed anhydrides with use of methyl chloroformate with triethylamine.

3) Another used method of synthesis is azeotropic dehydration of ammonium salt of appropriate (phenoxy)alkanoic acid with appropriate aminoalkanol.

4) Another method, used for achievement of some alkanolamides is synthesis with use of appropriate (phenoxy)alkanoic acid and aminoalkanol with presence of triethylamine and BOP (benzotriazol-1-yloxytris(dimethylaminophosphonium hexafluorophosphate)).

## Example 2. Description of synthesis of particular products

### 2.1 Synthesis of 2,6-dimethyl-, 2-chlor-6-methyl- phenoxyethanol

**[0020]** Solution of sodium ethanolate was prepared in a 750 ml round-bottomed flask (0.5 mole of sodium was dissolved in ethanol), to which 0.5 mole of appropriate phenol was added. The mixture was heated under reflux and in the boiling point a solution of 2-bromo- or 2-chloroethanol was added drop by drop for ca. 3 h. Afterwards, the mixture was heated for another 2 h and left to cool down. Precipitated white sediment (NaBr or NaCl) was filtered off, and the filtrate was distilled into oily residue. The residue was added 200 ml of water and 10% solution of NaOH (in order to get rid of the remaining phenol). Then extraction with benzene was performed, and organic phase was additionally washed with 10% NaOH, water, and dried with anhydrous  $\text{MgSO}_4$ . After distillation of the solvent, oily residue was achieved. The crude product was used for further bromination.

### 2.2. Synthesis of 2, 6-dimethyl-, 2-chlor-6-methyl-phenoxyalkylbromides

**[0021]** 0.15 mole of appropriate derivative of (phenoxy)ethanol was put into a 100 ml round-bottomed flask and 0.05 mole of  $\text{PBr}_3$  was slowly added. The mixture was heated for 1.5 h under reflux in water bath. Then the mixture was put into a flask with ice and neutralized with 15%  $\text{NaHCO}_3$ , and afterwards extraction with benzene was performed. After drying organic phase (anh.  $\text{MgSO}_4$ ), the solvent was distilled off, and oily residue was achieved. The crude product was used for further aminolysis.

### 2.3 Synthesis of 2,6-dimethyl-, 2-chlor-6-methyl-phenoxyalkylaminoalkanols

**[0022]** 0.012 mole of appropriate (phenoxy)ethyl bromide was put into a 100 ml round-bottomed flask. Then 0.012 mole of appropriate aminoalkanol and an excess of anh.  $\text{K}_2\text{CO}_3$  were added. The mixture was heated in toluene under reflux for ca. 5 h, and left to cool down. Afterwards silica gel was added and the mixture was heated again. The gel and precipitated KBr was filtered off and the remaining mixture was distilled into oily residue. Then 10% HCl and active carbon was added and the mixture was heated. Afterwards, the suspension was filtered off and the filtrate was alkalized with 10% NaOH in order to precipitate the free basis, which was extracted with benzene. The organic phase was dried (anh.  $\text{MgSO}_4$ ), and the organic solvent was distilled off until oily residue, which was crystallized.

### 2. 4 Synthesis of 2, 6-dimethyl-, 2-chlor-6-methyl-phenoxy acetic acid

**[0023]** Solution of 0.3 mole NaOH in 250 ml water was prepared in a 750 ml round-bottomed flask. Then 0.3 mole of appropriate phenol was added. Separately, 0.3 mole of chloroacetic acid in 300 ml 10%  $\text{NaHCO}_3$  was prepared in a flask, and the mixture was added to the formerly prepared solution of appropriate sodium phenolate and heated refluxed for 1 h.. Then active carbon was added, the mixture was filtered off from the suspension, and after cooling down the filtrate was acidified with 10% HCl. The precipitated acid, after filtering and drying, was crystallized from the mixture of heptane/toluene (1:1), and afterwards white crystal precipitate was achieved.

### 2.5 Synthesis of 2, 6-dimethyl-, 2-chlor-6-methyl-phenoxy acetic acid chlorides

**[0024]** 0.15 mole of appropriate (phenoxy)acetic acid was put into a 500 ml round-bottomed flask and 0.75 mole of  $\text{SOCl}_2$  ( $d=1.63 \text{ g/cm}^3$ ) was added, and the mixture was heated under reflux for ca. 30 min. Afterwards, excess of thionyl chloride was distilled off under reduced pressure, and the remaining liquid acid chloride was added toluene until 100ml and the solution of the crude chloride was used for the reactions with an appropriate aminoalkanol.

## 2. 6 Synthesis of 2,6-dimethyl-, 2-chlor-6-methyl-phenoxyacetyl aminoalkanol

[0025] 0.02 mole of appropriate aminoalkanol in 30 ml toluene was put in an Erlenmeyer flask, an excess of  $K_2CO_3$  was added dissolved in 50 ml of water. The mixture was cooled down and put on an electromagnetic stirrer. The mixture was added by small amounts a solution of appropriate (phenoxy)acetic chloride in toluene, and the emulsion was left on the stirrer for ca. 0.5 h and afterwards it was heated. After cooling the organic phase was separated and dried with anhydrous  $MgSO_4$ . Then the solvent was distilled off, and the residue was crystallized into a white precipitate of appropriate derivative.

## Example 3. Physicochemical data of some derivatives according to the invention

[0026] Physicochemical parameters (melting point M.p.,  $R_f$  for typical eluents, IR and  $^1H$  NMR spectra and/or optical rotation  $[\alpha]$ ) were measured for some achieved compounds, using standard analytical methods.

*R,S*-2*N*-[(2-chlor-6-methylphenoxy)ethyl]amino-1-butanol (26)

[0027] M.p.=68-69°C (toluene/heptane (1/1));  $R_f$ =0.56 (toluene/acetone (1/1));  $R_f$ =0.45 ( $CH_3OH$ /ethyl acetate (1/3)); IR (KBr,  $cm^{-1}$ )  $\nu$ : 3295, 3126, 3067, 2972, 2933, 2867, 2839, 1462, 1370, 1261, 1220;  $^1H$ -NMR: (500.13 MHz,  $DMSO-d_6$ ,  $\delta$  ppm) 7.28 (ddq,  $J=8.0$ ,  $J=1.6$ ,  $J=0.6$ , 1H, H-3); 7.18 (ddq,  $J=7.6$ ,  $J=1.6$ ,  $J=0.8$ , 1H, H-5); 7.03 (dd,  $J=8.0$ ,  $J=7.6$ ,  $J=0.4$ , 1H, H-4); 4.42 (t,  $J=5.2$ , 1H, OH); 3.93 (t,  $J=5.6$ , 2H, Ar- $OCH_2$ ); 3.42-3.37 (m, 1H,  $CHHOH$ ); 3.30-3.25 (m, 1H,  $CHHOH$ ); 2.96-2.86 (m, 2H,  $CH_2N$ ); 2.49-2.43 (m, 1H, CH); 2.28 (ddd,  $J=0.6$ ,  $J=0.8$ ,  $J=0.4$ , 3H,  $CH_3$ -Ar); 1.84 (bs, 1H, NH); 1.40-1.33 (m, 2H,  $CH_2Et$ ); 0.85 (t,  $J=7.5$ , 3H,  $CH_3(Et)$ ),  $C_{13}H_{20}NO_2Cl$  (257.77), [%]:  $N_{calc./analyzed}$ : 5.43/5.47;  $C_{calc./analyzed}$ : 60.58/60.59;  $H_{calc./analyzed}$ : 7.82/7.65.

*R,S*-2*N*-[(2-chlor-6-methylphenoxy)ethyl]amino-1-butanol hydrochloride (26a)

[0028] M.p.=108-110°C;  $R_f$ =0.68 ( $CH_3OH$ );  $R_f$ =0.59 ( $CH_3OH$ /ethyl acetate (1/1));  $^1H$ -NMR: (500.13 MHz,  $DMSO-d_6$ ,  $\delta$  ppm) 9.16 (bs, 1H,  $NH^+$ ); 8.97 (bs, 1H,  $H^+$ ); 7.32-7.04 (m, 3H, Ar); 5.39 (t,  $J=5.1$ , 1H,  $-O-CH_2-CHH-N$ ); 4.20 (t,  $J=5.9$ , 2H,  $-O-CH_2-$ ); 3.80-3.73 (m, 1H,  $-CHH-OH$ ); 3.61-3.57 (m, 1H,  $CHH-OH$ ); 3.39-3.33 (m, 2H,  $-O-CH_2-CHH-NH + OH$ ); 3.16-3.15 (m, 1H,  $-CH(C_2H_5)-CH_2OH$ ); 2.31 (s, 3H,  $CH_3Ar$ ); 1.80-1.68 (m, 2H,  $-CH_2-CH_3$ ); 0.92 (t,  $J=7.4$ , 3H,  $-CH_2-CH_3$ ),  $C_{13}H_{21}NO_2Cl_2$  (294.22), [%]:  $N_{calc./analyzed}$ : 4.76/4.72;  $C_{calc./analyzed}$ : 53.06/52.80;  $H_{calc./analyzed}$ : 7.20/7.60.

*R*-(-)-2*N*-[(2-chlor-6-methylphenoxy)ethyl]amino-1-butanol (27)

[0029] M.p.=66-68°C (toluene/heptane (1/1));  $R_f$ =0.56 (toluene/acetone (1/1));  $R_f$ =0.45 ( $CH_3OH$ /ethyl acetate (1/3)); IR (KBr,  $cm^{-1}$ )  $\nu$ : 3295, 3126, 3067, 2972, 2933, 2867, 2839, 1462, 1370, 1261, 1220;  $^1H$ -NMR: ( $CDCl_3$ , 300 MHz,  $\delta$  ppm) 7.26-6.92 (m, 3H, Ar); 4.08-3.97 (m, 2H, Ar- $O-CH_2$ ); 3.66 (dd,  $J=3.9$ ,  $J=10.6$ , 1H,  $CHH-OH$ ); 3.35 (dd,  $J=6.2$ ,  $J=10.6$ , 1H,  $CHH-OH$ ); 3.18-3.10 (m, 1H,  $O-CH_2-CHH-NH$ ); 2.96-2.85 (m, 1H,  $O-CH_2-CHH-NH$ ); 2.69-2.61 (m, 1H,  $NH-CH(C_2H_5)-CH_2OH$ ); 2.32 (s, 3H,  $CH_3$ -Ar); 1.63-1.40 (m, 2H,  $-CH_2-CH_3$ ); 0.96 (t,  $J=7.4$ , 3H,  $-CH_2-CH_3$ );  $C_{13}H_{20}NO_2Cl$  (257.77), [%]:  $N_{calc./analyzed}$ : 5.43/5.40;  $C_{calc./analyzed}$ : 60.58/60.26;  $H_{calc./analyzed}$ : 7.82/7.77; (c=1%,  $CHCl_3$ ):  $[\alpha]_{546}^{24.1}=-22.0^\circ$ ,  $[\alpha]_{589}^{22.7}=-20.94^\circ$ , ee=100%.

*R*-(-)-2*N*-[(2-chlor-6-methylphenoxy)ethyl]amino-1-butanol hydrochloride (27a)

[0031] M.p.=113-115°C;  $R_f$ =0.60 ( $CH_3OH$ /ethyl acetate (1/1));  $C_{13}H_{21}NO_2Cl_2$  (294.22), [%]:  $N_{calc./analyzed}$ : 4.76/4.75;  $C_{calc./analyzed}$ : 53.06/52.83;  $H_{calc./analyzed}$ : 7.20/7.19; (c=1%,  $CH_3OH$ ):  $[\alpha]_{589}^{23.3}=-1.6^\circ$ .

*S*-(+)-2*N*-(2-chlor-6-methylphenoxy)ethyl]amino-1-butanol (28)

[0032] M.p.=66-68°C (toluene/heptane (1/1));  $R_f$ =0.56 (toluene/acetone (1/1));  $R_f$ =0.45 ( $CH_3OH$ /ethyl acetate (1/3));  $^1H$ -NMR: ( $DMSO-d_6$ , 500.13 MHz,  $\delta$  ppm) 7.28 (dd,  $J=7.9$ ,  $J=1.7$ , 1H, H-3(Ar)); 7.18 (dd,  $J=7.6$ ,  $J=1.7$ , 1H, H-5(Ar)); 7.03 (dd,  $J=7.9$ ,  $J=7.6$ , 1H, H-4(Ar)); 4.47 (bs, 1H, OH); 3.93 (t,  $J=5.7$ , 2H, Ar- $O-CH_2$ ); 3.41 (dd,  $J=4.9$ ,  $J=10.6$ , 1H,  $CHH-OH$ ); 3.28 (dd,  $J=6.5$ ,  $J=10.6$ , 1H,  $CHH-OH$ ); 2.96-2.87 (m, 2H,  $-CH_2-N$ ); 2.49-2.42 (m, 1H,  $NH-CH(C_2H_5)-CH_2OH$ ); 2.28 (s, 3H,  $CH_3$ -Ar); 1.96 (bs, 1H, NH); 1.44-1.31 (m, 2H,  $-CH_2-CH_3$ ); 0.86 (t,  $J=7.6$ , 3H,  $-CH_2-CH_3$ ); (c=1%,  $CHCl_3$ ):  $[\alpha]_{546}^{24.1}=+21.00^\circ$ ;  $[\alpha]_{589}^{22.7}=+21.04^\circ$ , ee=100%.


*R,S*-2*N*-[(2,6-dimethylphenoxy)acetyl]amino-1-propanol (60)

[0033] M.p.=95-96°C;  $R_f$ =0.76 ( $CH_3OH$ /ethyl acetate (1/1));  $C_{13}H_{19}NO_3$  (237.30).


***R*-(+)-2*N*-[(2,6-dimethylphenoxy)acetyl]amino-1-propanol (61)****[0034]** M.p.=121-123°C;  $R_f$ =0.76 (CH<sub>3</sub>OH/ethyl acetate (1/1)); C<sub>13</sub>H<sub>19</sub>NO<sub>3</sub> (237.30).***S*-(-)-2*N*-[(2,6-dimethylphenoxy)acetyl]amino-1-propanol (62)****[0035]** M.p.=121-123°C;  $R_f$ =0.76 (CH<sub>3</sub>OH/ethyl acetate (1/1)); C<sub>13</sub>H<sub>19</sub>NO<sub>3</sub> (237.30).***R,S*-1*N*-[(2-chlor-6-methylphenoxy)acetyl]amino-2-butanol (72)**

**[0036]** M.p.=96-97°C;  $R_f$  = 0.70 (CH<sub>3</sub>OH/ethyl acetate (1/1)); IR (KBr, cm<sup>-1</sup>)  $\nu$ : 3421, 3337, 2969, 2921, 2878, 1655, 1541, 1458, 1225, 1045; <sup>1</sup>H-NMR: (DMSO-d<sub>6</sub>, 500.13 MHz,  $\delta$  ppm) 7.91 (dd,  $J$ =6.1,  $J$ =5.2, 1H, NH); 7.32 (dd,  $J$ =8.0,  $J$ =1.5, 1H, H-3); 7.21 (dd,  $J$ =7.6,  $J$ =1.5, 1H, H-5); 7.08 (dd,  $J$ =8.0,  $J$ =7.6, 1H, H-4); 4.73 (d,  $J$ =5.3, 1H, OH); 4.34 (s, 2H, O-CH<sub>2</sub>-C=O); 3.52-3.45 (m, 1H, CH); 3.26 (ddd,  $J$ =13.1,  $J$ =6.1,  $J$ =4.8, 1H, CHHC); 3.10 (ddd,  $J$ =13.1,  $J$ =6.9,  $J$ =5.2, 1H, CHHC); 2.30 (s, 3H, Ar-CH<sub>3</sub>); 1.48-1.19 (m, 1H, CHH(Et)); 1.36-1.26 (m, 1H, CHH(Et)); 0.88 (t,  $J$ =7.5, 3H, CH<sub>3</sub>(Et)), C<sub>13</sub>H<sub>18</sub>NO<sub>3</sub>Cl (271.75), [%]: N<sup>calc./analyzed</sup>: 5.15/5.24; C<sup>calc./analyzed</sup>: 57.46/58.02; H<sup>calc./analyzed</sup>: 6.67/6.60.

**Table 1. [(Phenoxy)ethyl]aminoalkanols**





|  |          |       |               |                                                                           |
|-----------------------------------------------------------------------------------|----------|-------|---------------|---------------------------------------------------------------------------|
| R                                                                                 | Compound | Z     | Configuration | Formula Mol. Mass                                                         |
| 2-Cl-6-CH <sub>3</sub>                                                            | 26       |       | <i>R,S</i>    | C <sub>13</sub> H <sub>20</sub> O <sub>2</sub> Cl<br>257.77               |
|                                                                                   | 26a      | x HCl | <i>R,S</i>    | C <sub>13</sub> H <sub>21</sub> NO <sub>2</sub> Cl <sub>2</sub><br>294.22 |
|                                                                                   | 27       |       | <i>R</i> -(-) | C <sub>13</sub> H <sub>20</sub> NO <sub>2</sub> Cl<br>257.77              |
|                                                                                   | 27a      | x HCl | <i>R</i> -(-) | C <sub>13</sub> H <sub>21</sub> NO <sub>2</sub> Cl <sub>2</sub><br>294.22 |
|                                                                                   | 28       |       | <i>S</i> -(+) | C <sub>13</sub> H <sub>20</sub> NO <sub>2</sub> Cl<br>257.77              |
|                                                                                   |          |       |               |                                                                           |

**Table 2. [(Phenoxy)acetyl]aminoalkanols**

|  |          |   |               |                   |
|-------------------------------------------------------------------------------------|----------|---|---------------|-------------------|
| R                                                                                   | Compound | Z | Configuration | Formula Mol. Mass |
| 2,6-(CH <sub>3</sub> ) <sub>2</sub>                                                 |          |   |               |                   |

## EP 2 247 571 B1

(continued)

| R | Compound | Z                                                                                 | Configuration | Formula Mol. Mass                                         |
|---|----------|-----------------------------------------------------------------------------------|---------------|-----------------------------------------------------------|
|   | 60       |  | R,S           | C <sub>13</sub> H <sub>19</sub> NO <sub>3</sub> 237.30    |
|   | 61       |  | R             | C <sub>13</sub> H <sub>19</sub> NO <sub>3</sub> 237.30    |
|   | 62       |  | S             | C <sub>13</sub> H <sub>19</sub> NO <sub>3</sub> 237.30    |
|   | 72       |  | R,S           | C <sub>13</sub> H <sub>18</sub> NO <sub>3</sub> Cl 271.75 |

**Example 4. Biological activity assays for achieved compounds**

**[0037]** The compounds in the invention were subject to pharmacological tests: MES (maximal electroshock seizures), ScMet (subcutaneous pentylenetetrazol) and TOX (neurotoxicity test) in mice and rats (intraperitoneal *i.p.* and oral *p.o.* administration).

**[0038]** In order to define anticonvulsant activity, screening tests were performed, using animal models of seizures. The tests were initially performed in mice (Carworth Farms No. 1), and if results proved activity - in rats (Sprague-Dawley). The tests were based on administration of a compound to an animal and after certain time inducing state similar to epilepsy attack in human. Each substance (after dissolving in methylcellulose) was normally tested in doses 30, 100, and 300 mg/kg body weight (b.w.) (mice) or in 30 and 50 mg/kg b.w. (rats) in two possible routes of administration: intraperitoneal (*i.p.*) or oral (*p.o.*). Appropriate tests were performed 0.5 and 4 h after administration of the compound. In cases of substances revealing activity in 30 mg/kg b.w. (mice) the tests were also performed in doses 10 and 3 mg/kg b.w.

**[0039] Maximum Electroshock Seizure (MES) test** is an electric test, verifying activity towards generalized tonic-clonic seizures (*grand mal* epilepsy) [9]. According to the literature, the most active compounds are those which inhibit voltage-gated sodium channels [10]. Its procedure consists in administration to an animal a mentioned dose, and after 0.5 or 4 h attaching corneal electrodes (after anesthetic eye-drops: 0.5% tetracaine hydrochloride in 0.9% NaCl) and turning on electric current (60 Hz, 0.2 s, 50 mA (mice) or 150 mA (rats)). If the tested substance reveals anticonvulsant activity, the used electric pulse will not reveal tonic-clonic seizures in the animal. Normally, in the dose 30 mg/kg b.w. the test is done in 1 mouse after 0.5 or 4 h, in the dose 100 mg/kg b.w. - in 3 mice, and in the dose 300 mg/kg b.w. - in 1 mouse [11-12].

**[0040] Subcutaneous Metrazol Test (ScMet)** is a chemical test, where compounds are tested for activity in absence seizures (*petit mal* epilepsy). Pentetrazol (metrazol) is considered to block chloride channel in the GABA<sub>A</sub> receptor complex, therefore at a certain dose in animals it causes myoclonic jerks, next - clonic seizures, and then tonic seizures. The procedure consists in administration of a tested compound and after 0.5 or 4 h subcutaneous administration of pentylenetetrazol in the dose of 85 mg/kg b.w. (mice) or 70 mg/kg b.w. (rats) in a 0.85% solution in 0.9% NaCl. The tested substance reveals anticonvulsant activity, if the dose of pentylenetetrazol does not induce seizures in the animal. Normally the test is performed in single animals.

**[0041] Neurotoxicity test (TOX)** is performed in order to eliminate substances exhibiting neurotoxicity. It is performed with use of rotarod test. The animal is placed on a plastic rod (1 inch in diameter), rotating 6 rpm. The rod is placed on a level discouraging the animal to jump off. If the tested compound (administered 0.5 or 4 h before the test) does not reveal neurotoxic effect (ataxia, sedation, excitation), the animal will keep its position on the rod for at least 1 min. Neurotoxicity is stated if the animal cannot stay on the rod for 1 min. in any of 3 trials [11]. Normally the test is performed in dose 30 mg/kg b.w. in 4 mice (0.5 h) and in 2 mice (4 h), in the dose 100 mg/kg b.w. in 8 mice (0.5 h) and in 4 mice (4 h) and in the dose 300 mg/kg b.w. in 4 mice (0.5 h) and 2 mice (4 h). It should be mentioned, that results of another commonly used test - chimney test - are concurrent with the described test [13].

**Results in mice**

**[0042]** Compounds according to claim 1 were subject to initial pharmacological screening. Their results are presented

## EP 2 247 571 B1

in Table 4 below.

Table 3

| Compd. | Dose [mg/kg b.w.] | Time [h]          |     |                     |   |                   |     |
|--------|-------------------|-------------------|-----|---------------------|---|-------------------|-----|
|        |                   | MES <sup>a)</sup> |     | ScMet <sup>a)</sup> |   | TOX <sup>b)</sup> |     |
|        |                   | 0.5               | 4   | 0.5                 | 4 | 0.5               | 4   |
| 26     | 3                 | -                 |     |                     |   | -                 |     |
|        | 10                | 2/4               |     |                     |   | -                 |     |
|        | 30                | 1/1               | -   | -                   | - | -                 | -   |
|        | 100               | 1/1               | -   |                     |   | 8/8               | -   |
|        | 300               |                   |     |                     |   | 4/4               |     |
| 26a    | 3                 | -                 | -   |                     |   | -                 |     |
|        | 10                | -                 |     |                     |   | -                 |     |
|        | 30                | 1/1               | -   | -                   | - | 3/4               | -   |
|        | 100               | 1/1               | -   |                     | - | 8/8               | 1/4 |
|        | 300               |                   |     |                     |   | 4/4               |     |
| 27     | 3                 | -                 |     |                     |   | -                 |     |
|        | 10                | -                 |     |                     |   | -                 |     |
|        | 30                | 1/1               | -   | -                   | - | -                 | -   |
|        | 100               | 1/1               | -   |                     |   | 8/8               | -   |
|        | 300               |                   |     |                     |   | 4/4               |     |
| 27a    | 30                | 1/1               | -   | -                   | - | -                 | -   |
|        | 100               | 2/3               | -   | -                   | - | 7/8               | -   |
|        | 300               |                   |     |                     |   | 4/4               |     |
| 28     | 30                | 1/1               | -   | -                   | - | -                 | -   |
|        | 100               | 1/1               |     |                     | - | 8/8               | -   |
|        | 300               |                   |     |                     |   | 4/4               |     |
| 60     | 30                | -                 | -   | -                   | - | -                 | -   |
|        | 100               | -                 | -   | -                   | - | 2/8               | 2/4 |
|        | 300               | 1/1               | -   | -                   | - | 4/4               | -   |
| 61     | 30                | -                 | -   | -                   | - | -                 | -   |
|        | 100               | -                 | -   | -                   | - | -                 | -   |
|        | 300               | 1/1               | -   | -                   | - | 2/4               | -   |
| 62     | 30                | -                 | -   | -                   | - | 1/4               | -   |
|        | 100               | -                 | -   | -                   | - | 3/8               | 1/4 |
|        | 300               | 1/1               | 1/1 | -                   | - | 3/4               | 1/2 |

## EP 2 247 571 B1

(continued)

| Compd.                                                                                                                                                                                         | Dose [mg/kg b.w.] | Time [h]          |   |                     |   |                   |   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-------------------|---|---------------------|---|-------------------|---|
|                                                                                                                                                                                                |                   | MES <sup>a)</sup> |   | ScMet <sup>a)</sup> |   | TOX <sup>b)</sup> |   |
|                                                                                                                                                                                                |                   | 0.5               | 4 | 0.5                 | 4 | 0.5               | 4 |
| 72                                                                                                                                                                                             | 30                | -                 | - | -                   | - | -                 | - |
|                                                                                                                                                                                                | 100               | -                 | - | -                   | - | -                 | - |
|                                                                                                                                                                                                | 300               | 1/1               | - | 1/1                 | - | 4/4               | - |
| <sup>a)</sup> No. of protected animals / No. of used animals; <sup>b)</sup> No. of animals exhibiting motor impairment / no. of used animals; - no activity or no neurotoxicity;   not tested. |                   |                   |   |                     |   |                   |   |

[0043] For the most active substances there are time to peak effect (TPE), ED<sub>50</sub> doses (the lowest dose active in 50% of animals), TD<sub>50</sub> (the lowest dose neurotoxic in 50% of animals) and protection index (PI) for intraperitoneal (*i.p.*) and oral (*p.o.*) administration.

[0044] For some compounds, a test for proconvulsant activity was performed (TTE test), as well as a test on activity in focal seizures (related with limbic system, 6 Hz test, hippocampal kindling). Activity in pharmacoresistant seizures has been revealed (lamotrigine-resistant amygdala kindling, rats, *i.p.*). A test on inhibiting seizures induced by sound (Frings mice) was performed for compounds 26-28. Electrophysiology tests also have been performed, for seizures induced by bicuculline, picrotoxin, and NMDA. Prevention of (pilocarpine induced) status epilepticus has been noticed.

[0045] Formalin test has revealed analgesic activity in the phase of **neuropathic pain** as well as **inflammatory pain**. Tests on mutagenic activity (Ames' and Vibrio harveyi) revealed broad safety in this matter. Tests in cytochromes P<sub>450</sub> for prediction of possible interaction with other drugs have revealed broad safety - non-competitive inhibition of CYP2D6 (K<sub>i</sub>=22.3 μM).

[0046] The formalin test has been performed for compound 26.

[0047] The test was performed with use of formaldehyde as a substance causing pain (neuropathic and inflammatory afterwards) in mice, which were injected formalin into a hind limb. The test used a dose of a tested substance equivalent to ED<sub>50</sub> (MES, mice, *i.p.*) administered 21.44 mg/kg b.w. to mice, *i.p.*, and after TPE time (MES, mice, *i.p.* = 0.25 h) formalin is administered in order to measure the time of reaction of the animals to the pain stimulus (licking the limb).


[0048] During the first 10 min. after administration the mouse is licking the hind limb (acute phase), afterwards there is a short break in behavior change, and then the mouse licks its limb again for another 20-30 min. (inflammatory phase) (Fig. 4 for 26). The acute phase represents direct affection on the peripheral nerve and the inflammatory phase is related with secretion of inflammation mediators from the damaged tissue and nerves. The described model tests effectiveness of a substance to inhibit acute and chronic excessive neuronal discharges in response to peripheral nerves activation.

[0049] Fig. 4 shows a graph representing calculated average results (time) for 8 animals in the test, at the dose 21 mg/kg b.w. (which is corresponding to MES ED<sub>50</sub> (mice, *i.p.*)=21.44 mg/kg b.w. As it can be noticed, compound 26 inhibits acute phase of the formalin test (first ca. 10 min. after formalin administration) (64% of control), which means analgesic activity in neuropathic pain. The results are statistically significant (p<0.01). Lowering pain in the inflammatory phase (72% of control) is not statistically significant. In order to fully interpret the results, Fig. 5 presents comparison with known antiepileptic drugs (AEDs) such as carbamazepine (CBZ) and valproic acid (VPA) in typical doses. The smaller % of AUC (area under curve) comparing to the control (methylcellulose, MC), and the shorter bar, the stronger analgesic activity. Therefore, it can be stated, that the compound is more effective than VPA in the acute phase, and less active in the inflammatory phase compared to VPA and CBZ.

[0050] All results were presented after TPE=0.25 h (as in MES). TD<sub>50</sub>s used for PI calculation were taken from the rotarod (TOX) test for neurotoxicity.

[0051] Comparison of activity of enantiomers **R-(-)** and **S-(+)-[(2-chlor-6-methylphenoxy)ethyl]amino-1-butanol** (compounds **27** i **28**, respectively).

[0052] Acute toxicity - minimal dose of substance (*i.p.*) causing acute motor impairment; the test uses at least 12 rats, observed for 4 h after administration (Graph 1).

**Graph 1 Measurement of compound 27 dose causing minimal motor impairment.**

**[0053] Status epilepticus prevention** - an animal (Sprague Dawley albino rat male) is given a dose of tested substance. After 0, 0.25, 0.5, 1, 2, and 4 h pilocarpine is administered. The seizures induced are described by Racine's score. Compounds **27** and **28** were administered *i.p.* in doses 25 and 45 mg/kg b.w. respectively. They both exhibit protection in 2 and 3 rats out of 8. The results are presented below. Average body weight loss is measured 24 h after administration.

**[0054]** Status epilepticus prevention of compounds 27 and 28.

**Table 4**

| Compound | Dose [mg/kg b.w.] | Time [h] | Protection | Average weight loss $\pm$ S.E.M. |
|----------|-------------------|----------|------------|----------------------------------|
| 27       | 25, <i>i.p.</i>   | 0        | 2/8        | 8,3 $\pm$ 7,1                    |
| 28       | 45, <i>i.p.</i>   | 0        | 3/8        | 3,8 $\pm$ 5,7                    |


**[0055]** As it can be noticed (Table 4), the doses needed for activity in this test is different for both enantiomers - *R* has proved to be more beneficial. However, in electric hippocampal kindling seizures in rats, *i.p.* it was *S* that proved more active. Therefore, it can be summarized, that enantiomer *R* is more effective in preventing status epilepticus, and *S* - in preventing limbic, focal seizures.

**[0056]** Below there are results for compounds **26** and **28**.

**26** TPETOX = 0.25 h; TPE<sub>MES</sub> = 0.25 h,  
**26** ED<sub>50</sub> (MES, mice, *i.p.*, 0.25 h) = **21.44** mg/kg b.w.; PI (MES, mice, *i.p.*) = **2.56**,  
**26** ED<sub>50</sub> (MES, rats, *p.o.*, 0.25 h) = **67.69** mg/kg b.w.; PI (MES, rats, *p.o.*) > **3.55**,  
**26** ED<sub>50</sub> (MES, rats, *i.p.*, 0.25 h) = **7.3** mg/kg b.w.; PI (MES, rats, *i.p.*) = **4.5**,  
**26** TPE (6 Hz, mice, *i.p.*, 32 mA) = 0.5 h,  
**28** ED<sub>50</sub> (kindling, rats, hippocampus, 0.25 h) = **15.81** mg/kg b.w.,  
**26** ((LTG- resistant amygdala seizures) t = 0.25 h; effective dose = **15** mg/kg b.w.,  
**26** ED<sub>50</sub> (sound induced seizures, mice, 0.25 h) = **6.05** mg/kg b.w.,  
**26** ED<sub>50</sub> (PIC, 0.25 h) > 70 mg/kg b.w.,  
**26** ED<sub>50</sub> (BIC, 0.25 h) > 70 mg/kg b.w.,  
**26** neuropathic pain inhibition (formalin test, 21 mg/kg b.w.) = **36%**.

**[0057]** Below there are pharmacological data for the optimum enantiomer *R*-(+)-2-[(2,6-dimethylphenoxy)acetyl]amino-1-propanol (compound **61**):

## EP 2 247 571 B1



**[0058]** ED<sub>50</sub> (MES, mice, *i.p.*) = 97.93 mg/kg b.w.

**[0059]** PI (MES, mice, *i.p.*) = 1.43

## References

**[0060]**

1 Fischer W.: Anticonvulsant profile and mechanism of action of propranolol and its two enantiomers. *Seizure* 11: 285-302 (2002).

2 Alexander G. J., Kopeloff L. M., Alexander R. B., Chatterjee N.: Mexiletine: biphasic action on convulsive seizures in rodents. *Neurobehav. Toxicol. Teratol.* 8: 231-235 (1986).

3 Chew C. Y. C., Collett J., Singh B. N.: Mexiletine: A Review of its Pharmacological Properties and Therapeutic Efficacy in Arrhythmias. *Drugs* 17: 161-181 (1979).

4 Orlof M. J., Williams H. L., Pfeiffer C. C.: Timed intervenous infusion of metrazol and strychnine for testing anti-convulsant drugs. *Proc. Soc. Exp. Biol. Med.* 70: 254-257 (1949).

5 Marona H., Antkiewicz-Michaluk L.: Synthesis and anticonvulsant activity of 1,2-aminoalkanol derivatives. *Acta Pol. Pharm. - Drug Res.* 55: 487-498 (1998).

6 Waszkielewicz A.M., Cegla M., Marona H.: Preliminary evaluation of anticonvulsant activity of some [4-(benzyloxy)-benzoyl]- and [4-(benzyloxy)-benzyl]-aminoalkanol derivatives. *Acta Pol. Pharm. Drug Res.* 64, 147-157 (2007).

7 Pekala E., Gajewczyk L., Marona H.: Synthesis of New N-acyl Derivatives of DL-trans-1,2-Aminocyclohexanol. *Acta Pol. Pharm. -Drug Res.* 51: 339-342 (1994).

8 Marona H., Pękala E.: *Synthesis of Some N-acyl Derivatives of Optically Active trans-2-Amino-1-cyclohexanols.* *Acta Pol. Pharm. - Drug Res.* 53: 111-115 (1996).

9 Swinyard E. A., Woodhead J. H., White, H. S., Franklin M.R.: General principles: experimental selection, quantification, and evaluation of anticonvulsants. *Antiepileptic Drugs*, Str. 85-102, Wyd. 3. Raven Press, Nowy Jork 1989.

10 Rogawski M. A., Porter R. J.: Antiepileptic Drugs: Pharmacological Mechanisms and Clinical Efficacy with Consideration of Promising Developmental Stage Compounds. *Pharmacol. Rev.* 42: 223-286 (1990).

11 Stables J. P., Kupferberg H. J.: The NIH Anticonvulsant Drug Development (ADD) Program: preclinical anticonvulsant screening project. Chapter 16. [http://www.ninds.nih.gov/funding/research/asp/addadd\\_review.pdf](http://www.ninds.nih.gov/funding/research/asp/addadd_review.pdf)

12 Kupferberg H.: Animal Models Used in the Screening of Antiepileptic Drugs. *Epilepsia* 42: 7-12 (2001).

13 Czuczwar S. J., Borowicz K. K., Kleinrok Z., Tutka P., Zamowski T., Turski W. A.: Influence of Combined Treatment with NMDA and Non-NMDA Receptor Antagonists on Electroconvulsions in Mice. *Eur. J. Pharmacol.* 281: 327-333 (1995)

14 "Preliminary evaluation of anticonvulsant activity of some aminoalkanol derivatives" 15th International Symposium "Molecular and Physiological Aspects of Regulatory Processes of the Organism", Cracow, June 1-2, 2006, Anna M. Waszkielewicz, Marek Cegla, Henryk Marona

**EP 2 247 571 B1**

15 "Synthesis and Anticonvulsant Activity of 1,2-Aminoalkanol Derivatives" Acta Poloniae Pharmaceutica - Drug Res, 55, 487-498, 1998 Marona H, Antkiewicz-Michaluk L.

5 16 "Preliminary Evaluation of Anticonvulsant Activity of Some Aroxyacetamides and Aroxyethylamines" Acta Pol. Pharm. - Drug Res. 62: 345-352, 2005:D5: Marona H., Waszkielewicz AM, Szneler E

17 Polish Patent Application No. P 319 557 Marona Henryk, Filipek Barbara, Uniwersytet Jagielloński Collegium Medicum, Polish Patent Office 1997.

**Patentkrav**

1. Aminoalkanolderivat, valgt fra gruppen omfattende:
  - R,S*-2*N*-[(2-klor-6-methylphenoxy)ethyl]amino-1-butanol (26)
  - 5 *R,S*-2*N*-[(2-klor-6-methylphenoxy)ethyl]amino-1-butanol hydroklorid (26a)
  - R*-(-)-2*N*-[(2-klor-6-methylphenoxy)ethyl]amino-1-butanol (27)
  - R*-(-)-2*N*-[(2-klor-6-methylphenoxy)ethyl]amino-1-butanol hydroklorid (27a)
  - S*-(+)-2*N*-[(2-klor-6-methylphenoxy)ethyl]amino-1-butanol (28)
  - 10 *R,S*-2*N*-[(2,6-dimethylphenoxy)acetyl]amino-1-propanol (60)
  - R*-(+)-2*N*-[(2,6-dimethylphenoxy)acetyl]amino-1-propanol (61)
  - S*-(-)-2*N*-[(2,6-dimethylphenoxy)acetyl]amino-1-propanol (62)
  - R,S*-1*N*-[(2-klor-6-methylphenoxy)acetyl]amino-2-butanol (72)
- 15 2. Anvendelse af forbindelse ifølge krav 1 til fremstilling af et lægemiddel som anvendelse i profylaksen, forebyggelsen og/eller behandlingen af sygdomme eller symptomer af neurologisk baggrund.
3. Anvendelse ifølge krav 2, hvor en sygdom eller et symptom af neurologisk
  - 20 baggrund er en epilepsi, i særdeleshed grand-mal epilepsi, psykomotorisk epilepsi, fokalanfald, status epilepticus, myoklon anfald eller anfald af forskellige oprindelser (lyd, lys, kemisk stimulus, genetisk oprindelse, neuronalskade), såvel som neuropatisk eller inflammatorisk smerte.
- 25 4. Anvendelse ifølge krav 2, hvor det fremstillede lægemiddel er et analgetikum, antiinflammatorisk, anti-krampemiddel eller antiepileptikum.
5. Anvendelse ifølge krav 2, hvor en sygdom eller et symptom er neuropatisk smerte, omfattende smerte af forskellig etiologi: diabetisk neuropati, cancer
  - 30 smerte, AIDS neuropati, rygmarvsskade, fantomsmerter, eller fibromyalgi.
6. Fremgangsmåde til opnåelse af derivater af aminoalkanoler ifølge krav 1,
 

**kendetegnet ved at** N-alkylation af aminoalkanolerne med egnede (phenoxy)alkyl bromider fremstilles ved at tilføje 0,010 – 0,015 mol af egnet

(phenoxy)ethyl bromid i en 100 ml flaske, derefter 0,010 – 0,015 mol af egnet

- aminoalkanol og et overskud af anh.  $K_2CO_3$ , derefter varmes blandingen i toluol under reflux i ca. 3-15 timer, og efterlades til nedkøling, efterfølgende tilføjes silica gel og blandingen varmes igen, gelen og præcipiteret KBr filtreres væk og den resterende blanding destilleres til en olierest, derefter tilføjes 10-20% HCl og
- 5 aktiveret kul og blandingen varmes, efterfølgende filtreres suspensionen væk og filtratet alkaliseres med 5-20% NaOH for at præcipitere den fri base, som ekstraheres med benzen eller toluol, den organiske fase tørres (anh.  $MgSO_4$ ), og det organiske solvent destilleres væk indtil olierest, som krystalliseres.
- 10 **7.** Fremgangsmåde til opnåelse af aminoalkanoler ifølge krav 1, **kendetegnet ved at** *N*-Acetylation af aminoalkanolerne med anvendelse af klorid af egnet (phenoxy)alkanoinsyre i bifasisk miljø (toluol/vand) med tilstedeværelse af  $K_2CO_3$  fremstilles, hvor 0,015 – 0,025 mol af egnet aminoalkanol i 30 ml toluol puttes i en flaske, et overskud af  $K_2CO_3$  tilføjes opløst i 50 ml vand, blandingen nedkøles
- 15 og sat på en omrører, derefter tilføjes blandingen i små mængder en opløsning af egnet (phenoxy)eddike klorid i toluol, og emulsionen efterlades på omrøreren i ca. 0,5 time og efterfølgende varmes, efter køling separeres og tørres den organiske fase med anh.  $MgSO_4$ , derefter destilleres solventen væk, og resterne krystalliseres til et hvidt præcipitat af egnet derivat.




Fig. 1




Fig. 2




Fig. 3